Australia markets open in 7 hours 15 minutes
  • ALL ORDS

    7,728.50
    +1.30 (+0.02%)
     
  • AUD/USD

    0.7490
    -0.0028 (-0.37%)
     
  • ASX 200

    7,415.40
    +1.70 (+0.02%)
     
  • OIL

    80.94
    -2.48 (-2.97%)
     
  • GOLD

    1,780.40
    -4.50 (-0.25%)
     
  • BTC-AUD

    83,844.43
    -5,748.64 (-6.42%)
     
  • CMC Crypto 200

    1,484.06
    -50.59 (-3.30%)
     

Global Non-Invasive Prenatal Testing (NIPT) Market to Reach $9.7 Billion by 2027

·26-min read

Abstract: - Global Non-Invasive Prenatal Testing (NIPT) Market to Reach $9. 7 Billion by 2027. - Amid the COVID-19 crisis, the global market for Non-Invasive Prenatal Testing (NIPT) estimated at US$4.

New York, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-Invasive Prenatal Testing (NIPT) Industry" - https://www.reportlinker.com/p06032345/?utm_source=GNW
3 Billion in the year 2020, is projected to reach a revised size of US$9.7 Billion by 2027, growing at a CAGR of 12.2% over the analysis period 2020-2027. Ultrasound Detection, one of the segments analyzed in the report, is projected to record a 12.5% CAGR and reach US$5.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biochemical Screening Tests segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 16.1% CAGR
- The Non-Invasive Prenatal Testing (NIPT) market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 16% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.
- Cell-free DNA in Maternal Plasma Tests Segment to Record 12.8% CAGR
- In the global Cell-free DNA in Maternal Plasma Tests segment, USA, Canada, Japan, China and Europe will drive the 12% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$518.7 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.4 Billion by the year 2027, while Latin America will expand at a 14.3% CAGR through the analysis period.

- Select Competitors (Total 33 Featured) -

  • Agilent Technologies, Inc.

  • Berry Genetics Inc.

  • BGI Genomics Co. Ltd.

  • Eurofins LifeCodexx GmbH

  • F. Hoffmann-La Roche Ltd.

  • GE Healthcare

  • Igenomix

  • Illumina, Inc.

  • Laboratory Corporation of America Holdings

  • Natera, Inc.

  • PerkinElmer Inc.

  • Thermo Fisher Scientific Inc.

  • Yourgene Health




Read the full report: https://www.reportlinker.com/p06032345/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Ultrasound
Detection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Ultrasound Detection by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Ultrasound Detection by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biochemical
Screening Tests by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biochemical Screening Tests
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Biochemical Screening
Tests by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 10: World Current & Future Analysis for Cell-free DNA in
Maternal Plasma Tests by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Cell-free DNA in Maternal
Plasma Tests by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Cell-free DNA in
Maternal Plasma Tests by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 13: World Current & Future Analysis for Trisomy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Trisomy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Trisomy by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Microdeletion
Syndrome by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Microdeletion Syndrome by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Microdeletion Syndrome
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Diagnostic
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Diagnostic Laboratories by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Diagnostic Laboratories
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Non-Invasive Prenatal Testing
(NIPT) by Method - Ultrasound Detection, Biochemical Screening
Tests and Cell-free DNA in Maternal Plasma Tests Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 31: USA Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 32: USA Historic Review for Non-Invasive Prenatal Testing
(NIPT) by Application - Trisomy, Microdeletion Syndrome and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Non-Invasive Prenatal Testing
(NIPT) by End-Use - Diagnostic Laboratories and Hospitals
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

CANADA
Table 37: Canada Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 40: Canada Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 41: Canada Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

JAPAN
Table 46: Japan Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 49: Japan Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 50: Japan Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

CHINA
Table 55: China Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 58: China Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 59: China Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

EUROPE
Table 64: Europe Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 66: Europe 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 70: Europe Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 71: Europe Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

FRANCE
Table 76: France Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 79: France Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 80: France Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

GERMANY
Table 85: Germany Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 88: Germany Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 89: Germany Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Germany 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 91: Germany Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

ITALY
Table 94: Italy Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: Italy Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 96: Italy 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 97: Italy Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 98: Italy Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Italy 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 100: Italy Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 103: UK Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: UK Historic Review for Non-Invasive Prenatal Testing
(NIPT) by Method - Ultrasound Detection, Biochemical Screening
Tests and Cell-free DNA in Maternal Plasma Tests Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 105: UK 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 106: UK Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 107: UK Historic Review for Non-Invasive Prenatal Testing
(NIPT) by Application - Trisomy, Microdeletion Syndrome and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 108: UK 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 109: UK Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 110: UK Historic Review for Non-Invasive Prenatal Testing
(NIPT) by End-Use - Diagnostic Laboratories and Hospitals
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 111: UK 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

SPAIN
Table 112: Spain Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 113: Spain Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 114: Spain 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 115: Spain Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 116: Spain Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 117: Spain 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Application - Percentage Breakdown of Value
Sales for Trisomy, Microdeletion Syndrome and Other
Applications for the Years 2012, 2020 & 2027

Table 118: Spain Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by End-Use - Diagnostic Laboratories
and Hospitals - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Diagnostic Laboratories and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 120: Spain 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by End-Use - Percentage Breakdown of Value Sales
for Diagnostic Laboratories and Hospitals for the Years 2012,
2020 & 2027

RUSSIA
Table 121: Russia Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Method - Ultrasound Detection,
Biochemical Screening Tests and Cell-free DNA in Maternal
Plasma Tests - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 122: Russia Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Method - Ultrasound Detection, Biochemical
Screening Tests and Cell-free DNA in Maternal Plasma Tests
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 123: Russia 15-Year Perspective for Non-Invasive Prenatal
Testing (NIPT) by Method - Percentage Breakdown of Value Sales
for Ultrasound Detection, Biochemical Screening Tests and
Cell-free DNA in Maternal Plasma Tests for the Years 2012, 2020 &
2027

Table 124: Russia Current & Future Analysis for Non-Invasive
Prenatal Testing (NIPT) by Application - Trisomy, Microdeletion
Syndrome and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 125: Russia Historic Review for Non-Invasive Prenatal
Testing (NIPT) by Application - Trisomy, Microdeletion Syndrome
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032345/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting